Imaging Changes in Liver Cancer with Nitroglycerin
This study is looking at how a medication called nitroglycerin, given directly into the artery (intra-arterially), affects blood flow in liver tumors (hepatocellular carcinoma or HCC). Researchers will use a special imaging technique called Parenchymal Blood Volume (PBV) imaging to see these changes. You might be able to join if you are an adult with newly diagnosed HCC that your doctors have decided is suitable for a standard treatment called trans-arterial chemoembolization (TACE). The main goal is to see if at least 30% of participants show an increase in blood flow to their tumor on the first day after receiving nitroglycerin. The current recruitment status is unclear.
- Study design
- This is a single-arm, open-label study involving about 50 participants. It is a first-in-human feasibility study.
- What's involved
- You would undergo PBV imaging before and after receiving intra-arterial nitroglycerin during your standard TACE treatment. You would then have follow-up appointments on days 3, 7, 30, and 90 after the procedure.
- Compensation
- Not stated in the trial record.
- Follow-up
- Participants will be followed for 90 days after the procedure.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Utilize Imaging to Assess Changes in Hepatocellular Carcinoma Perfusion as Potentiated by Intra-Arterial Nitroglycerin
At a glance
Conditions
NCT07682454
Where you'd take part
This study runs at 2 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.
University of California, San Francisco
San Francisco, Californiastudy coordinator listed
Zuckerberg San Francisco General Hospital (ZSFG)
San Francisco, Californiastudy coordinator listed
Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.
Study leadership
- Christopher Brunson, MD · PRINCIPAL_INVESTIGATOR · University of California, San Francisco
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Proportion of Participants with >= 30% increase in Tumoral Blood VolumeDay 1
Proportion of participants who demonstrate an increase in tumoral blood volume of at least 30% following intra-arterial nitroglycerin administration compared with pre-nitroglycerin baseline along with Bonferroni-corrected confidence intervals will be reported.